PetCaseFinder

Peer-reviewed veterinary case report

Using acute phase proteins to diagnose and treat steroid-responsive

By Lowrie, M et al.·Published in Veterinary journal (London, England : 1997)·2009·Faculty of Veterinary Medicine, United Kingdom·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: The role of acute phase proteins in diagnosis and management of steroid-responsive meningitis arteritis in dogs.

Species:
dog
Brain & nervesDogs

Plain-English summary

A 5-year-old Beagle was brought in for neck pain and reluctance to move, which led to a diagnosis of steroid-responsive meningitis arteritis (SRMA), an inflammatory condition. The veterinarian monitored the dog's response to treatment by checking levels of certain proteins in the blood, known as acute phase proteins (APPs). These proteins helped confirm the diagnosis and track the effectiveness of treatment. After starting steroids, the dog's APP levels decreased, indicating a positive response to therapy. However, one protein level increased, which could suggest a potential relapse. Overall, the dog showed improvement with treatment and was more comfortable.

People also search for: dog neck pain · Beagle meningitis treatment · steroid-responsive meningitis in dogs

Abstract

Acute phase proteins (APPs) have become an important tool in the diagnosis, management and prognosis of inflammatory diseases in humans and are developing a similar utility in domestic species. Steroid-responsive meningitis arteritis (SRMA) is a well-recognised inflammatory disease of the dog, the diagnosis of which remains unsatisfactory based on clinical criteria and non-specific laboratory investigations. In this prospective pilot study the authors examined the acute phase response throughout the course of SRMA in serum and cerebrospinal fluid (CSF) by evaluating three key stages in disease management: presentation, treatment response and putative relapse. Serum APPs were found to be of value in supporting the diagnosis of SRMA and monitoring its treatment. C-reactive protein (CRP), serum amyloid-A (SAA), alpha-1-acid glycoprotein (AGP) and haptoglobin (Hp) all exhibited an increase above our laboratory reference range in nine patients at initial presentation. During treatment APPs decreased significantly compared to presentation except Hp which increased (Wilcoxon-Signed-Rank-test: CRP, SAA and AGP P<0.05). Serum CRP and SAA were also found to be of clinical value in the identification of putative relapse (seven cases), particularly in the light of unperturbed CSF parameters where APP concentrations were elevated. CSF APPs were found to be less reliable markers in the management of this disease. The results indicate that SRMA causes a significant APP response in dogs, which although not disease specific, is of value in supporting the diagnosis of SRMA.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18590973/